Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. 1993

P Lipponen
Department of Pathology, University of Kuopio, Finland.

Paraffin embedded tissue from 249 transitional cell bladder cancers (TCC) was stained by an antibody against c-erbB-2 oncoprotein to evaluate its overexpression. The staining results were related to histopathological features and clinical follow-up data. 99/249 (39%) of tumours were positive for c-erbB-2 oncoprotein and 31/249 (12.5%) of them showed moderate or heavy staining. c-erbB-2 overexpression was related to pelvic lymph node involvement (P = 0.0355) and distant metastasis (P = 0.0058) at the time of diagnosis, whereas no significant relationship was found between T-category and c-erbB-2 oncoprotein overexpression. Expression of c-erbB-2 was related to high WHO grade (P = 0.0033), DNA aneuploidy (P = 0.0061), high S-phase fraction (P = 0.042), and several morphometric nuclear factors (P = 0.01-0.09). All the tumours with high levels of c-erbB-2 expression were tetraploid in flow cytometry (P < 0.0001). c-erbB-2 expression predicted recurrence-free survival in superficial tumours (P = 0.057) and in survival analysis moderate or intense expression of c-erbB-2 oncoprotein was related to decreased survival probability (P = 0.27). In multivariate survival analysis overexpression of c-erbB-2 had no independent prognostic value. The results show that immunohistochemical demonstration of c-erbB-2 oncoprotein overexpression in paraffin embedded archival material has no prognostic value over already established predictors in TCC.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
Copied contents to your clipboard!